Abingworth Management

Abingworth Management is a distinguished investment firm that has been at the forefront of the life sciences and healthcare sectors since its establishment in 1973. With its headquarters in London and additional offices in Menlo Park and Boston, the firm focuses on identifying and nurturing companies in the United States and Europe that are poised to revolutionize healthcare. Abingworth's investment expertise encompasses a broad spectrum, including healthcare services, medical devices, diagnostics, pharmaceuticals, and nucleic acid therapeutics. Believing in the transformative power of breakthrough science, Abingworth collaborates closely with entrepreneurs to turn innovative ideas into viable medical solutions. The firm offers not only capital but also invaluable time, patience, and experience, enabling biopharmaceutical companies to transition from scientific discovery to therapeutic application. Since making its inaugural investment in a biotech startup in 1987, Abingworth has successfully funded over a hundred companies, demonstrating a commitment to fostering growth and advancement within the life sciences sector. With a hands-on approach, Abingworth Management leverages its extensive network and knowledge to provide tailored support to its portfolio companies. Their team of seasoned professionals brings a wealth of experience across various scenarios and stages in the life sciences industry, ensuring that entrepreneurs receive the guidance needed to navigate the complexities of bringing new treatments to market. Innovation is a cornerstone of Abingworth's strategy, not only for the companies it invests in but also within its own operational framework. The firm has pioneered unique investment strategies, such as VIPEs (Venture Investments in Public Equities) and Clinical Co-Development, which are designed to maximize returns while also facilitating groundbreaking advancements in healthcare. By focusing on the intersection of innovation and investment, Abingworth enables its partner companies to address critical unmet medical needs. Strategically positioned between major biotech hubs in Europe and the United States, Abingworth provides entrepreneurs with essential transatlantic access to new developments and opportunities. This geographical advantage enhances collaboration and knowledge exchange, further solidifying the firm’s role as a bridge connecting innovative companies with the resources they need to succeed. Abingworth’s portfolio is diverse, encompassing investments across early and seed stages to later stage, growth, expansion, PIPE (Private Investment in Public Equities), and buyout investments. The firm typically engages in investments ranging from a minimum of $30,950,000 to its maximum fund investment size, reflecting its robust financial capacity and commitment to supporting the next generation of biopharma enterprises. Through its specialized strategies and deep industry knowledge, Abingworth Management plays a pivotal role in advancing the field of life sciences. The firm is dedicated to empowering entrepreneurs and healthcare innovators, fostering an environment where cutting-edge research can flourish and translate into effective treatments for patients. As Abingworth continues to pursue transformative opportunities and champion the development of groundbreaking medical solutions, it remains a leader in the investment landscape, dedicated to enhancing global health outcomes.